Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger

Catalyst Pharmaceuticals stockholders approved the company’s merger with Angelini Pharma at a special meeting held on July 8.

Under the deal, Angelini Cello Inc. will merge into Catalyst, and Catalyst will become a wholly owned subsidiary of Angelini Pharma.

The merger proposal passed with the required vote of a majority of Catalyst’s outstanding shares entitled to vote.

Company officials said the final voting results will be announced publicly after certification.

A separate non-binding compensation advisory proposal did not receive stockholder approval, but it was not a condition for completing the merger.

Because the merger proposal passed, no adjournment vote was needed and the meeting was concluded.

Catalyst Pharmaceuticals NASDAQ: CPRX stockholders approved the company’s proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company officials during the meeting.

Patrick J. McEnany, chairman of Catalyst’s board of directors, presided over the meeting and said stockholders were asked to vote on three matters described in the company’s definitive proxy statement.

The central item was the adoption of the agreement and plan of merger dated May 6, 2026, among Catalyst, Angelini Pharma S.p.A. and Angelini Cello Inc., a Delaware corporation and wholly owned subsidiary of Angelini Pharma.

Under the merger agreement described at the meeting, Angelini Cello Inc. will merge with and into Catalyst, with Catalyst surviving the transaction as a wholly owned subsidiary of Angelini Pharma.

Stockholders Approve Merger Proposal...